Piloting Pathways With Lung Cancer Patients

Condition:   Metastatic Lung Cancer Intervention:   Behavioral: Pathways Sponsors:   Laurie McLouth;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionsThese two urinary proteins could serve as potential markers for the diagnosis of NSCLC.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
ConclusionsTSMA predicts adverse outcome after pneumonectomy for lung cancer. This marker, readily derived from standard chest CT, identifies patients at increased risk for postoperative complications and may help select patients appropriate for focused rehabilitation prior to pneumonectomy.Graphical abstract
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
MONDAY, Dec. 9, 2019 -- For newly diagnosed patients with non-small cell lung cancer (NSCLC), depressive symptoms are common and often accompanied by other symptoms, according to a study published online Nov. 21 in Lung Cancer. Barbara L. Andersen,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Authors: Seiz JR, Klinke J, Scharlibbe L, Lohfink D, Heipel M, Ungefroren H, Giehl K, Menke A Abstract Rac1 is a ubiquitously expressed Rho GTPase and an important regulator of the actin cy-toskeleton. Its splice variant Rac1b exhibits a 19aa in-frame insertion and is predominantly active. Both proteins were described in tumorigenesis or metastasis. We investigated the contribution of Rac1 and Rac1b to tumor progression of human non-small-cell-lungadenocarcinoma (NSCLA). Rac1 protein was present in 8/8 NSCLA cell lines analyzed, whereas Rac1b was expressed in only 6/8. In wound healing assays, EGFP-Rac1 slightly de...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
Oncogene, Published online: 09 December 2019; doi:10.1038/s41388-019-1130-xCorrection: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
AbstractAs part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresectable, stage III non-small cell lung cancer whose tumours express programmed death-ligand 1 (PD-L1) on  ≥ 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation therapy. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University Medi...
Source: PharmacoEconomics - Category: Health Management Source Type: research
ConclusionsOur results indicate that compared with crizotinib and alectinib, ceritinib is a cost-effective option for treatment-na ïve patients with ALK-positive advanced NSCLC.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Authors: Kim SY, Lee S, Lee E, Lim H, Shin JY, Jung J, Kim SG, Moon A Abstract There is a wide disparity in the incidence, malignancy and mortality of different types of cancer between each sex. The sex-specificity of cancer seems to be dependent on the type of cancer. Cancer incidence and mortality have been demonstrated as sex-specific in a number of different types of cancer, such as liver cancer, whereas sex-specificity is not noticeable in certain other types of cancer, including colon and lung cancer. The present study aimed to elucidate the molecular basis for sex-biased gene expression in cancer. The mRNA e...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
This study investigated the effect of miR-133a on cell proliferation in non-small cell lung cancer (NSCLC). The expression of miR-133a and YES proto-oncogene 1 (YES1) was detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. The CCK-8 assay was used to measure cell proliferation. The relationship between miR-133a and YES1 was confirmed by dual luciferase assay. Downregulation of miR-133a was identified in NSCLC and correlated with poor prognosis in NSCLC patients. Moreover, the overexpression of miR-133a inhibited proliferation of NSCLC cells. YES1 was also confirmed as a direct targe...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, Grosso A, Roviello G, Mazzanti R, Santomaggio C, Mini E Abstract The use of vinorelbine as single agent or in combination regimens in NSCLC is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not widely explored. Eighty-one patient treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, 44 vinor...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Research